China

Closeup of blue eye on black background
Biotech

Innovent eyes China approval after matching Eylea in phase 3

Innovent’s prospect matched Bayer and Regeneron’s Eylea, teeing up filings for Chinese approval of a molecule that could cut maintenance dosing.
Nick Paul Taylor Mar 24, 2026 6:00am
NVS
Favicon Fierce Pharma

Novartis pledges nearly $480M to bolster China production, R&D

Mar 23, 2026 10:35am
Graphic of a puzzle depicting both the US and Chinese flags with missing pieces bridging the two together

Syneos Health scoops up Chinese CRO

Mar 19, 2026 11:00am
AstraZeneca
Favicon Fierce Pharma

AZ to build cell therapy supply hub, R&D center in Shanghai

Mar 19, 2026 10:20am
Shanghai China at sunrise

China approves 1st brain-computer implant for paralyzed patients

Mar 13, 2026 11:27am
Graphic of a puzzle depicting both the US and Chinese flags with missing pieces bridging the two together

Tenacia pens $308M Rapport deal for China rights to epilepsy med

Mar 9, 2026 10:30am